FFF Enterprises: BioSupply Trends Newsletter
Monday, July 17, 2017

Recombinant Quadrivalent Flublok Vaccine More Effective in Older Adults

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

A clinical trial comparing the protective efficacy in older adults of a quadrivalent recombinant influenza vaccine (RIV4) with a standard-dose, egg-grown quadrivalent, inactivated influenza vaccine during the A/H3N2-predominant 2014-2015 influenza season showed RIV4 provided better protection against confirmed influenza-like illness among adults aged 50 and older. [ read more ]

Public Attitudes Toward Unvaccinated Children and Their Mothers Depends on Reasons

A study conducted at the University of British Columbia found that mothers are viewed negatively if their child hasn’t been vaccinated, regardless of the reason; however, mothers who refuse to vaccinate their children are viewed in a harsher light compared with those who delay vaccination because of safety concerns or time constraints. [ read more ]

Study Shows Influenza May Increase Risk of Developing Parkinson’s

New research suggests a certain strain of influenza virus predisposes mice to developing pathologies that mimic those seen in Parkinson’s disease, a risk that could be decreased with influenza vaccine protection. [ read more ]

Industry News

 
 

From ADMA Biologics

ADMA Biologics has acquired Biotest Pharmaceuticals’ Therapy Business Unit, and now owns the marketing rights to Nabi-HB (hepatitis B immune globulin, human) and Bivigam (immune globulin intravenous, human). [ read more ]

From Seqirus

Seqirus has successfully produced a cell-based influenza vaccine using a candidate vaccine virus that has been isolated and grown in cells, rather than in eggs.  [ read more ]

From CSL Behring

CSL Behring has received the National Organization of Rare Disorders’ 2017 Industry Award for IDELVION, its long-acting fusion protein for patients with hemophilia B. [ read more ]

IVIG & Albumin Supply Index

 
 

Featured Products

HyperRAB® S/D (Grifols)

HyperRAB S/D and the rabies vaccine should be given to all persons suspected of exposure to rabies with one exception: persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine. HyperRAB S/D should be administered as promptly as possible after exposure, but can be administered up to the eighth day after the first dose of vaccine is given. HyperRAB S/D is preservative and latex-free and comes in 2 mL and 10 mL vial sizes.

For more information about HyperRAB S/D, login to biosupply.fffenterprises.com

HyperRHO® S/D (Grifols)

HyperRHO S/D Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D) negative mother within 72 hours after birth of an Rho(D) positive infant. HyperRHO S/D Full Dose may be used to prevent isoimmunization in Rho(D) negative individuals who have been transfused with Rho(D) positive red blood cells or blood components containing red blood cells. HyperRHO S/D Full Dose comes in a 300 ugm single-dose syringe and a 1 mL syringe (10 pack).

HyperRHO S/D Mini-Dose is recommended to prevent the isoimmunization of Rho(D) negative women at the time of spontaneous or induced abortion of up to 12 weeks' gestation. HyperRHO S/D Mini-Dose is available in a 50 ugm single-dose syringe (10 pack).

For more information about HyperRHO S/D, login to biosupply.fffenterprises.com

 

What's New at FFF

SODIUM PHENYLACETATE AND SODIUM BENZOATE (MYLAN)

SODIUM PHENYLACETATE AND SODIUM BENZOATE (injection) is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. It is supplied in a 10%/10% concentrated, aqueous solution.

For more information about SODIUM PHENYLACETATE AND SODIUM BENZOATE,
login to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective July 1, 2017, through Sept. 30, 2017.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Carimune NF J1566 $65.88 $64.83
Flebogamma J1572 $55.86 $54.96
Gammagard S/D J1566 $65.88 $64.83
Gammaplex J1557 $93.38 $91.88
Octagam J1568 $68.25 $67.16
Privigen J1459 $77.21 $75.97
SCIG
CUVITRU ** J3490/J3590/J7799 - -
Hizentra J1559 $98.29 $96.71
HyQvia J1575 $130.36 $128.27
IVIG / SCIG
Gammagard Liquid J1569 $80.39 $79.10
Gammaked J1561 $76.82 $75.59
Gamunex-C J1561 $76.82 $75.59

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2017 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.